CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin
Hiroyuki Yazawa, Tsuyoshi Hiraiwa, Fumihiro Ito, Keiya Fujimori
Obstet Gynecol Sci. 2017;60(6):587-592.   Published online October 17, 2017
DOI: https://doi.org/10.5468/ogs.2017.60.6.587

Excel Download

Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin
Obstetrics & Gynecology Science. 2017;60(6):587   Crossref logo
Link1 Link2 Link3

PRO: Dose-dense Paclitaxel in Combination with Carboplatin is an Acceptable Standard in the Front-Line Management of Advanced Stage Ovarian Cancer
Clinical Ovarian Cancer. 2011;4(1):1-3   Crossref logo
Link1 Link2

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
The Lancet Oncology. 2013;14(10):1020-1026   Crossref logo
Link1 Link2

“Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma” Safra T, et al (Gynecol Oncol 2009; 114:215-218)
Gynecologic Oncology. 2009;115(3):514   Crossref logo
Link1 Link2

Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma
Gynecologic Oncology. 2009;115(3):514-515   Crossref logo
Link1 Link2

Carboplatin/paclitaxel
Reactions Weekly. 2018;1721(1):70-70   Crossref logo
Link1 Link2 Link3

Dose-Dense Weekly Paclitaxel and Carboplatin Is More Cost-Effective Than Bevacizumab Plus Triweekly Paclitaxel and Carboplatin for the Primary Treatment of Advanced Ovarian Cancer
Annals of Oncology. 2012;23:ix320-ix321   Crossref logo
Link1 Link2

Long-Term Survival and Disease Recurrence in Patients With Primary Squamous Cell Carcinoma of the Vulva
Yearbook of Obstetrics, Gynecology and Women's Health. 2006;2006:419-420   Crossref logo
Link1 Link2

267PD Survival, clinical activity and safety of intraperitoneal carboplatin combined with intravenous dose-dense paclitaxel in patients with ovarian carcinoma: a retrospective study of 69 cases
Annals of Oncology. 2015;26:ix80   Crossref logo
Link1 Link2

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
Yearbook of Oncology. 2009;2009:36-37   Crossref logo
Link1 Link2